NCT03728023View on ClinicalTrials.gov

A Study of AZD4205 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

August 20, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

AZD4205

SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days

DRUG

Placebo

Single dose in SAD and once daily for 14 days

Trial Locations (1)

07094

Frontage clinical service, Secaucus

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY